BiotechTube
Nacuity Pharmaceuticals

Nacuity Pharmaceuticals

Fort Worth, United States· Est.
nacuity.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $17M

Overview

Nacuity Pharmaceuticals is a privately held, Fort Worth-based biotech founded in 2017, targeting oxidative stress as a root cause of disease. The company is advancing a pipeline of first-of-a-kind small molecule therapies, with its most advanced program, NPI-001, in Phase 2/3 development for retinitis pigmentosa. Led by a seasoned team with deep expertise in ophthalmology and drug development, particularly from Alcon Laboratories, Nacuity aims to deliver disease-modifying treatments for underserved patient populations. Its platform has potential applications beyond ophthalmology into other chronic conditions driven by oxidative damage.

OphthalmologyRare Diseases

Technology Platform

Small molecule therapies targeting oxidative stress to halt tissue damage.

Funding History

2
Total raised:$17M
Grant$2M
Series A$15M

Opportunities

Validating its oxidative stress platform in retinitis pigmentosa could unlock applications for a wide range of chronic diseases beyond ophthalmology.
The lack of any approved disease-modifying drug for RP presents a major commercial opportunity for a first-to-market therapy.
A successful pharmacological treatment for cataract could tap into a massive global market and shift the standard of care from surgery to early intervention.

Risk Factors

The lead program faces high clinical trial risk, as failure in Phase 2/3 would significantly impact company value.
As a pre-revenue private company, it is dependent on raising capital, with associated dilution and funding runway risks.
Competition in the retinal disease space is intensifying with gene and cell therapies, and convincing adoption of a drug for cataract against entrenched surgical practice is a major commercial challenge.

Competitive Landscape

In retinitis pigmentosa, Nacuity competes with gene therapy companies (e.g., Spark Therapeutics, Biogen), neuroprotective agents, and other approaches from firms like jCyte and ReNeuron. The cataract space has virtually no pharmacological competition, but must displace a highly effective surgical standard. In cystinosis, it would compete with and potentially complement existing cysteamine therapies.

More companies in Small Molecule Drugs →More companies in United States →